Hypertension in Wilms Tumor at Diagnosis: Proposed Treatment Recommendations Starting From a Bi‐Institutional Retrospective Observational Study
Alessandra Bondanese, Giovanna Gattuso, Vittoria Hassan, Marta Giorgia Podda, Valeria Colombo, Giulia Zucchetti, Chiara Novara, Francesca Torchio, Lucia Mauri, Sara Pizzamiglio, Paolo Verderio, Licia Peruzzi, Giovanni Montini, Franca Fagioli, Maura Massimino, Paola Quarello, Filippo SpreaficoABSTRACT
Background
Arterial hypertension (AH) is a common clinical finding at the time of Wilms tumor (WT) diagnosis, is often difficult to manage, and is potentially related to acute complications.
Methods
We retrospectively analyzed 147 patients with newly diagnosed WT treated between January 2010 and December 2023 at two high‐volume Italian pediatric oncology centers. Demographic, clinical, treatment, and tumor characteristics were evaluated in relation to the presence of AH.
Results
At WT diagnosis, 75/147 (51%) of patients were hypertensive. Large tumor volume (continuous variable, p = 0.011), advanced tumor stage ( p = 0.012), bilateral disease ( p = 0.015), and renal vascular involvement ( p = 0.004) were significantly associated with AH. Calcium channel blockers were the most frequently used antihypertensive agents, followed by angiotensin converting enzyme inhibitors. Six out of 75 (8%) of patients suffered from secondary complications related to AH.
Conclusions
We confirmed the high prevalence of AH at WT diagnosis and identified tumor‐related factors associated with an increased risk of developing AH. The key elements for the adequate management of these patients include the use of appropriate antihypertensive therapy and proper routine blood pressure screening for all patients with a new WT diagnosis.
In the absence of standardized treatment guidelines, we propose recommendations developed through collaboration among pediatric oncologists, cardiologists, and nephrologists.
Trial Registration
EudraCT number 2016‐004180‐39